The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial
Open accessAbstract
Background Preeclampsia complicates approximately 3% to 5% of pregnancies and remains a major cause of maternal and neonatal morbidity and mortality. It shares pathogenic similarities with adult cardiovascular disease as well as many risk factors. Pravastatin, a hydrophilic, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor, has been shown in preclinical studies to reverse various pathophysiological pathways associated with preeclampsia, providing biological plausibility for its use for preeclampsia prevention. However, human trials are lacking. Objective As an initial step in evaluating the utility of pravastatin in preventing preeclampsia, and after consultation with the U.S. Food and Drug Administration, we undertook a pilot randomized controlled trial with the objective to determine pravastatin safety and pharmacokinetic parameters when used in pregnant women at high risk of preeclampsia. Study Design We conducted a pilot, multicenter, double-blind, placebo-controlled, randomized trial of women with singleton, non-anomalous pregnancies at high risk for preeclampsia. Women between 120/7 and 166/7 weeks gestation were assigned to daily pravastatin 10 mg or placebo orally until delivery. Primary outcomes were maternal-fetal safety and pharmacokinetic parameters of pravastatin during pregnancy. Secondary outcomes included rates of preeclampsia and preterm delivery, gestational age at delivery, birthweight, and maternal and cord blood lipid profile (Clinicaltrials.gov Identifier NCT01717586). Results Ten women assigned to pravastatin and ten to placebo completed the trial. There were no differences between the two groups in rates of study drug side effects, congenital anomalies, or other adverse or serious adverse events. There was no maternal, fetal, or neonatal death. Pravastatin renal clearance was significantly higher in pregnancy compared to postpartum. Four subjects in the placebo group developed preeclampsia compared to none in the pravastatin group. Although pravastatin reduced maternal cholesterol concentrations, umbilical cord cholesterol concentrations and infant birthweight were not different between the groups. The majority of umbilical cord and maternal pravastatin plasma concentrations at time of delivery were below the lower limit of quantification of the assay. Conclusions This study provides preliminary safety and pharmacokinetic data regarding the use of pravastatin for preventing preeclampsia in high-risk pregnant women. Although the data are preliminary, no identifiable safety risks were associated with pravastatin use in this cohort. This favorable risk-benefit analysis justifies using pravastatin in a larger clinical trial with dose escalation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
(2013) · doi:10.1097/01.aog.0000437382.03963.88 · Cited by 3,961
Onuegbu, A. J., Olisekodiaka, J. M., Udo, J. U., Umeononihu, O., Amah, U. K., Okwara, J. E., & Atuegbu, C. (2015) · Medical Principles and Practice · doi:10.1159/000381778 · Cited by 2,044
Practice bulletin #33: diagnosis and management of preeclampsia and eclampsia
ACOG Committee on Obstetric Practice (2002) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(01)01747-1 · Cited by 1,058
Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data
Askie, L. M., Duley, L., Henderson-Smart, D. J., & Stewart, L. A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60712-0 · Cited by 1,020
Brugts, J. J., Yetgin, T., Hoeks, S. E., Gotto, A. M., Shepherd, J., Westendorp, R. G. J., de Craen, A. J. M., Knopp, R. H., Nakamura, H., Ridker, P., et al. (2009) · BMJ · doi:10.1136/bmj.b2376 · Cited by 792 · cited 1×
“On the contrary, inhibitors of 3-hydroxy-3-methylglutarylcoenzyme-A (HMG-CoA) reductase (statins) are effective in primary and secondary prevention of cardiovascular mortality and morbidity (10,11).”
BackgroundYoung, B. C., Levine, R. J., & Karumanchi, S. A. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102149 · Cited by 719
Risk of pre-eclampsia in first and subsequent pregnancies: prospective cohort study
Hernandez-Diaz, S., Toh, S., & Cnattingius, S. (2009) · BMJ · doi:10.1136/bmj.b2255 · Cited by 566
Mongraw-Chaffin, M. L., Cirillo, P. M., & Cohn, B. A. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.150078 · Cited by 434
Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments
Mills, E. J., Rachlis, B., Wu, P., Devereaux, P. J., Arora, P., & Perri, D. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.08.039 · Cited by 423
Negative Regulation of Soluble Flt-1 and Soluble Endoglin Release by Heme Oxygenase-1
Cudmore, M., Ahmad, S., Al-Ani, B., Fujisawa, T., Coxall, H., Chudasama, K., Devey, L. R., Wigmore, S. J., Abbas, A., Hewett, P. W., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.660134 · Cited by 421
Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model
Kumasawa, K., Ikawa, M., Kidoya, H., Hasuwa, H., Saito-Fujita, T., Morioka, Y., Takakura, N., Kimura, T., & Okabe, M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011293108 · Cited by 367
Prediction and Prevention of Recurrent Preeclampsia
Barton, J. R., & Sibai, B. M. (2008) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181801d56 · Cited by 309
Pfeffer, M. A., Keech, A., Sacks, F. M., Cobbe, S. M., Tonkin, A., Byington, R. P., Davis, B. R., Friedman, C. P., & Braunwald, E. (2002) · Circulation · doi:10.1161/01.cir.0000017634.00171.24 · Cited by 241
Statins and congenital malformations: cohort study
Bateman, B. T., Hernandez-Diaz, S., Fischer, M. A., Seely, E. W., Ecker, J. L., Franklin, J. M., Desai, R. J., Allen-Coleman, C., Mogun, H., Avorn, J., et al. (2015) · BMJ · doi:10.1136/bmj.h1035 · Cited by 236
Clinical Pharmacokinetics of Pravastatin: Mechanisms of Pharmacokinetic Events
Hatanaka, T. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200039060-00002 · Cited by 224
Pre-Eclampsia: Clinical Manifestations and Molecular Mechanisms
Baumwell, S., & Karumanchi, S. A. (2007) · Nephron Clinical Practice · doi:10.1159/000101801 · Cited by 210
Edison, R. J., & Muenke, M. (2004) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.30386 · Cited by 206
Woollett, L. A. (2005) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/82.6.1155 · Cited by 206
Role of Complement Component C1q in the Onset of Preeclampsia in Mice
Singh, J., Ahmed, A., & Girardi, G. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.175919 · Cited by 187
Singhvi, S., Pan, H., Morrison, R., & Willard, D. (1990) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1990.tb03626.x · Cited by 179
Pravastatin for the Prevention of Preeclampsia in High-Risk Pregnant Women
Costantine, M. M., & Cleary, K. (2013) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31827d8ad5 · Cited by 161
Self-citationIs inflammation the cause of pre-eclampsia?
Ramma, W., & Ahmed, A. (2011) · Biochemical Society Transactions · doi:10.1042/bst20110672 · Cited by 152
A New Mouse Model to Explore Therapies for Preeclampsia
Ahmed, A., Singh, J. K., Khan, Y., Seshan, S. V., & Girardi, G. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013663 · Cited by 146
Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes
Taguchi, N., Rubin, E. T., Hosokawa, A., Choi, J., Ying, A. Y., Moretti, M. E., Koren, G., & Ito, S. (2008) · Reproductive Toxicology · doi:10.1016/j.reprotox.2008.06.009 · Cited by 142
Hasegawa, M., Kusuhara, H., Sugiyama, D., Ito, K., Ueda, S., Endou, H., & Sugiyama, Y. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.746 · Cited by 141
Costantine, M. M., Tamayo, E. H., Lu, F., Bytautiene, E., Longo, M., Hankins, G. D. V., & Saade, G. R. (2010) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e3181e10ebd · Cited by 138
Self-citationRisk of congenital anomalies in pregnant users of statin drugs
Ofori, B., Rey, É., & Bérard, A. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02905.x · Cited by 133
Pregnancy outcome following maternal exposure to statins: a multicentre prospective study
Winterfeld, U., Allignol, A., Panchaud, A., Rothuizen, L. E., Merlob, P., Cuppers‐Maarschalkerweerd, B., Vial, T., Stephens, S., Clementi, M., Santis, M. D., et al. (2012) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.12066 · Cited by 126
Fox, K. A., Longo, M., Tamayo, E. H., Kechichian, T. B., Bytautiene, E., Hankins, G. D. V., Saade, G. R., & Costantine, M. M. (2011) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2011.06.083 · Cited by 96
Self-citationSaad, A. F., Kechichian, T. B., Yin, H., Sbrana, E., Longo, M., Wen, M., Tamayo, E. H., Hankins, G. D. V., Saade, G. R., & Costantine, M. M. (2013) · Reproductive Sciences · doi:10.1177/1933719113492207 · Cited by 88
Self-citationTransplacental transfer and distribution of pravastatin
Nanovskaya, T. N., Patrikeeva, S., Paúl, J., Costantine, M. M., Hankins, G. D. V., & Ahmed, M. S. (2013) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2013.05.038 · Cited by 78
Self-citationMaternal exposure to statins and risk for birth defects: A case‐series approach
Petersen, E. E., Mitchell, A. A., Carey, J. C., Werler, M. M., Louik, C., & Rasmussen, S. A. (2008) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.32493 · Cited by 73
Influence of maternal lipid profile on placental protein expression of LDLr and SR-BI
Ethier-Chiasson, M., Duchesne, A., Forest, J., Giguère, Y., Masse, A., Mounier, C., & Lafond, J. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.05.002 · Cited by 67
Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase.
Pan, H. Y. (1991) · PubMed · Cited by 44
The transfer of pravastatin in the dually perfused human placenta
Żarek, J. A., DeGorter, M. K., Lubetsky, A., Kim, R. B., Laskin, C. A., Berger, H. M., & Koren, G. (2013) · Placenta · doi:10.1016/j.placenta.2013.05.002 · Cited by 38
Cited by
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691
Pre-eclampsia: pathophysiology and clinical implications
Burton, G. J., Redman, C. W., Roberts, J. M., & Moffett, A. (2019) · BMJ · doi:10.1136/bmj.l2381 · Cited by 1,250
Pre-eclampsia: pathogenesis, novel diagnostics and therapies
Phipps, E. A., Thadhani, R., Benzing, T., & Karumanchi, S. A. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0119-6 · Cited by 1,191
Chappell, L. C., Cluver, C. A., Kingdom, J., & Tong, S. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32335-7 · Cited by 925
Metadata
- Authors
- Costantine, M. M., Cleary, K., Hebert, M. F., Ahmed, M. S., Brown, L. M., Ren, Z., Easterling, T. R., Haas, D. M., Haneline, L. S., Caritis, S. N., Venkataramanan, R., West, H., D’Alton, M., & Hankins, G.
- Venue
- American Journal of Obstetrics and Gynecology
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 214
- Issue
- 6
- Pages
- 720.e1-720.e17
- ISSN
- 0002-9378 (ISSN-L)
- OpenAlex
- W2210639700
- Cited by
- 275
- References
- 36
- FWCI
- 22.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.